Samaya B
☆    

India,
2014-07-03 15:18
(4375 d 19:45 ago)

Posting: # 13211
Views: 4,052
 

 Topical ointment Clinical Trial US and EU [Design Issues]

Dear All,

Greetings!

We are developing a topical ointment (5-Fluorouracil) for US and EU.

US reference product is manufactured by Valeant in Canada.
EU reference product is manufactured by Meda in Poland.

As of now we plan to conduct three arm study (Test product, US reference product, Placebo) to file in US. Is there any chance that MHRA (EU regulatory authority) will accept this study?? or we should include EU reference product as well i.e. four arm study (Test product, US reference product, EU reference product, Placebo)?

Secondly, if four arm study is conducted then MHRA and FDA would accept the statistical significance of clinical data?

Lastly, whether study should include subjects from different parts of India / US /EU or only Indian population would suffice??

Your views will be really helpful for further Proceedings.

Thank you.


Regards,
Samaya.


Edit: Category changed. [Helmut]
ElMaestro
★★★

Denmark,
2014-07-03 16:05
(4375 d 18:58 ago)

@ Samaya B
Posting: # 13212
Views: 3,273
 

 Topical ointment Clinical Trial US and EU

Hello Samaya,

❝ We are developing a topical ointment (5-Fluorouracil) for US and EU.

❝ As of now we plan to conduct three arm study (Test product, US reference product, Placebo) to file in US. Is there any chance that MHRA (EU regulatory authority) will accept this study?? or we should include EU reference product as well i.e. four arm study (Test product, US reference product, EU reference product, Placebo)?


Almost zero chance for EU approval without an EU-sourced ref. product, I think.

❝ Secondly, if four arm study is conducted then MHRA and FDA would accept the statistical significance of clinical data?


Likely, yes. But you should get sc. advice first to have confirmed that they will accept the US-inspired protocol. Or you should submit in a non-UK country country as RMS in a DCP - this can radically increase your chance of success even in the UK., even if this sounds a bit counter-intuitive to you.

❝ Lastly, whether study should include subjects from different parts of India / US /EU or only Indian population would suffice??


I don't think that populations should affect the success proportion of T vs R. So my guess -and I stress: this is a guess- is that Indian subjects would be OK for approval in both US and EU. As I read the US guidance, little is dictated re. the origin of the subjects.

Pass or fail!
ElMaestro
UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
289 visitors (0 registered, 289 guests [including 20 identified bots]).
Forum time: 11:04 CEST (Europe/Vienna)

Ignorance more frequently begets confidence
than does knowledge.    Charles Darwin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5